Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens-Reference-Cited by-同舟云学术

Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens

Published:2020-03 Issue:3 Volume:32 Page:440-446
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

El-Khayat Hisham,Kamal Enas M.,Mahmoud Hani,Gomaa Ahmed,Ebeid Bassel,Sameh Yehia,Hasseb Alaa,El Raziky Maissa,El Serafy Magdy,Doss Wahid,Esmat Gamal,Fouad Yasser,Attia Dina

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference33 articles.

1. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.;Razavi;J Viral Hepat,2014

2. Hepatitis C infection in Egypt: prevalence, impact and management strategies.;Gomaa;Hepat Med,2017

3. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.;Poordad;J Viral Hepat,2012

4. Sofosbuvir plus daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.;Shiha;Hepatol Int,2018

5. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.;El-Khayat;Aliment Pharmacol Ther,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antivirals;Reactions Weekly;2021-01

2. Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies;Journal of Viral Hepatitis;2020-08-03